[
1. BURT AD., LACKNER C., TINIAKOS D. Diagnosis and Assessment of MASLD: Definitions and Histopathological Classification. Semin Liver Dis. 2015; 35:207-20.
]Search in Google Scholar
[
2. WONG RJ., AGUILAR M., CHEUNG R., PERUMPAIL RB., HARRISON SA., YOUNOSSI ZM., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148:547-55.
]Search in Google Scholar
[
3. BOURSIER J., DIEHL AM. Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease. PLoS Pathog. 2015; 11: e1004559.
]Search in Google Scholar
[
4. VAJRO P., PAOLELLA G., FASANO A. Microbiota and gut-liver axis: A mini-review on their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013; 56:461–468.
]Search in Google Scholar
[
5. ZHOU X., WANG J., ZHOU S., LIAO J., YE Z., MAO L. Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. Medicine (Baltimore). 2023;102:e32734.
]Search in Google Scholar
[
6. JUNGERSEN M., WIND A., JOHANSEN E., CHRISTENSEN JE., STUER-LAURIDSEN B., ESKESEN D. The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12(®). Microorganisms. 2014; 2:92-110.
]Search in Google Scholar
[
7. OU Y., CHEN S., REN F., ZHANG M., GE S., GUO H.,et al. Lactobacillus casei Strain Shirota Alleviates Constipation in Adults by Increasing the Pipecolinic Acid Level in the Gut. Front Microbiol. 2019;10:324.
]Search in Google Scholar
[
8. KOIZUMI Y., HIROOKA M., TAMAKI N., YADA N., NAKASHIMA O., IZUMI N., et al. New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. PLoS One. 2019;14:e0221548.
]Search in Google Scholar
[
9. CAPORASO JG., LAUBER CL., WALTERS WA., BERG-LYONS D., HUNTLEY J., FIERER N., et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISMEJ. 2012; 6:1621-4.
]Search in Google Scholar
[
10. EDGAR RC. UPARSE: Highly Accurate OTU Sequences from Microbial Amplicon Reads. Nat Methods. 2013. 1: 996–8.
]Search in Google Scholar
[
11. DIMENÄS E., CARLSSON G., GLISE H., ISRAELSSON B., WIKLUND I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl. 1996; 221:8-13.
]Search in Google Scholar
[
12. ASNICAR F., LEEMING ER., DIMIDI E., MAZIDI M., FRANKS PW., AL KHATIB H., et al. Blue poo: impact of gut transit time on the gut microbiome using a novel marker. Gut. 2021;70:1665-74.
]Search in Google Scholar
[
13. Raosoft Software. Calculate Your Sample Size. http://www.raosoft.com/samplesize.html Date accessed 3rd January 2021.
]Search in Google Scholar
[
14. AHN SB., JUN DW., KANG BK., LIM JH., LIM S., CHUNG MJ. Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci Rep. 2019; 9:5688.
]Search in Google Scholar
[
15. Bomhof MR., Parnell JA., Ramay HR., Crotty P., Rioux KP., Probert CS., et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. 2019; 58:1735-1745.
]Search in Google Scholar
[
16. Duseja A., Acharya SK., Mehta M., Chhabra S., Shalimar., Rana S., et al. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (MASLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol. 2019; 6:e000315.
]Search in Google Scholar
[
17. Kobyliak N., Abenavoli L., Mykhalchyshyn G., Kononenko L., Boccuto L., Kyriienko D., et al. A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in MASLD Patients: Evidence from a Randomized Clinical Trial. J Gastrointestin Liver Dis. 2018; 27:41-9.
]Search in Google Scholar
[
18. MCFARLANE C., RAMOS CI., JOHNSON DW., CAMPBELL KL. Prebiotic, Probiotic, and Synbiotic Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-analysis. J Ren Nutr. 2019; 29:209-220.
]Search in Google Scholar
[
19. ARAI N, MIURA K, AIZAWA K, SEKIYA M, NAGAYAMA M, SAKAMOTO H, et al. (2022). Probiotics suppress nonalcoholic steatohepatitis and carcinogenesis progression in hepatocyte-specific PTEN knockout mice. Scientific Reports 2022; 12: 1-12.
]Search in Google Scholar
[
20. HENKE MT, KENNY DJ, CASSILLY CD, VLAMAKIS H, XAVIER RJ, CLARDY J. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci U S A 2019; 116:12672-7.
]Search in Google Scholar
[
21. BALDELLI V., SCALDAFERRI F., PUTIGNANI L., DEL CHIERICO F. The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases. Microorganisms. 2021; 9:697.
]Search in Google Scholar
[
22. NAGPAL R., SHIVELY CA., REGISTER TC., CRAFT S., YADAV H. Gut microbiome-Mediterranean diet interactions in improving host health. F1000Res. 2019; 8:699.
]Search in Google Scholar
[
23. LEE G., YOU HJ., BAJAJ JS., JOO SK., YU J., PARK S., et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese MASLD. Nat Commun 2020; 11:4982.
]Search in Google Scholar
[
24. ROMANÍ-PÉREZ M., LÓPEZ-ALMELA I., BULLICH-VILARRUBIAS C., RUEDA-RUZAFA L., GÓMEZ DEL PULGAR EM., BENÍTEZ-PÁEZ A., et al. Holdemanella biformis improves glucose tolerance and regulates GLP-1 signaling in obese mice. FASEB J. 2021; 35:e21734.
]Search in Google Scholar
[
25. NEWSOME PN., BUCHHOLTZ K., CUSI K., LINDER M., OKANOUE T., RATZIU V., et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021; 384:1113-1124.
]Search in Google Scholar
[
26. GUDAN A., JAMIOŁ-MILC D., HAWRYŁKOWICZ V., SKONIECZNA-ŻYDECKA K., STACHOWSKA E. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: MASLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients 2022; 14:5261.
]Search in Google Scholar
[
27. TAKAKURA W, PIMENTEL M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. Front Psychiatry 2020;11:664.
]Search in Google Scholar
[
28. SCHATTENBERG JM. Intestinal motility: a therapeutic target for MASLD? Lancet Gastroenterol Hepatol. 2020; 5:957-958.
]Search in Google Scholar
[
29. KESSOKU T., IMAJO K., KOBAYASHI T., OZAKI A., IWAKI M., HONDA Y., et al. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2020; 5:996-1007.
]Search in Google Scholar
